Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-RAD202 in HER2 Expressing Advanced Solid Tumours
NCT06824155Phase 1Recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Nanobodies (VHH), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RAD202 in solid tumor, sponsored by Radiopharm Theranostics. Primary endpoints: Safety and tolerability of 177Lu-RAD202 at 6 weeks and Recommended dose(s) of 177Lu-RAD202 for future exploration at 6 weeks. Started Feb 2025; status: recruiting.
02
Drugs
RAD202
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06824155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824155.